In a prospective randomized study, the efficacy and safety of 1 and 2 g of
cefodizime administered as single
intramuscular injections were compared in a total of 50 women having either complicated or uncomplicated lower
urinary tract infections (LUTI). Bacteriological culture of urine and safety laboratory tests were performed before and
after treatment. 18/25 patients in the 1 g
cefodizime group and 22/25 in the 2 g
cefodizime group showed satisfactory clinical and bacteriological response to treatment. The inadequately treated patients all had complicating factors on entry to the study (residual urine in six cases, a bladder
malignancy in two,
neurogenic bladder and
diabetes mellitus with glucosuria in one case each).
Cefodizime proved efficacious in female patients with uncomplicated LUTI, as well as in those aged over 65 years, patients having mild
renal insufficiency, mild glucosuria, unsuccessful oral
antibiotic pretreatment or recurrent and postoperative
infections. In no case were there any systemic adverse reactions to
cefodizime or clinically significant changes in laboratory tests.